Selank and DSIP on TikTok: separating signal from noise

What's this video probably claiming?

Based on the hashtags and creator handle, @peptidegirl464 is almost certainly pitching selank and DSIP (delta sleep-inducing peptide) as part of a biohacking stack, possibly alongside GLP-1 adjacent content. The framing is likely something along the lines of: selank reduces anxiety without sedation, DSIP fixes your sleep architecture, and together they optimize stress and recovery in ways that prescription drugs supposedly can't. The GLP-1 hashtag suggests she may be positioning these peptides as complements to semaglutide or tirzepatide, perhaps claiming they counteract cortisol spikes that undermine weight loss. This is a pattern in the peptide biohacking space right now. Creators conflate promising preclinical data with proven human outcomes, wrap it in personal testimony, and let the algorithm do the rest. The problem is not that these peptides are useless. The problem is the certainty with which they're being sold to 8,900 people who have no clinical relationship with anyone reviewing their health history.

What does the science actually show?

Selank is a synthetic hexapeptide developed by the Russian Institute of Molecular Genetics. It has actual published clinical data, which is more than most peptides in this space can claim. Zozulya et al. (2008, CNS Drug Reviews) reported anxiolytic effects in a small randomized trial of 60 patients with generalized anxiety disorder, with selank showing comparable effects to medazepam without measurable sedation. That is legitimately interesting. However, the doses used were 400 mcg intranasally, the trial was conducted in Russia, and the study has never been replicated in a large Western randomized controlled trial. DSIP is older, first isolated in 1977 by Monnier et al. (Science), and the sleep induction claims trace back to rabbit studies where its infusion into the thalamus reduced wakefulness. Human data is sparse. Graf and Kastin (1984, Neuroscience and Biobehavioral Reviews) reviewed 20 years of DSIP research and concluded the evidence was inconsistent and mechanistically unclear. Forty years later, that summary still holds. Neither peptide has FDA approval for any indication.

Where does the social media noise diverge from clinical reality?

The gap between TikTok peptide content and actual clinical evidence is wide, and selank and DSIP are good examples of why. Social media creators typically cite the Russian clinical literature on selank without acknowledging that Russian regulatory standards differ from FDA or EMA requirements, and that institutional independence in those trials is difficult to verify. The biohacking community also treats intranasal bioavailability as equivalent to IV administration in study conditions, which is not supported by pharmacokinetic data. For DSIP, the claim that it "resets sleep architecture" is not substantiated by human polysomnography studies. The peptide has an extremely short half-life (estimated under 30 minutes in human plasma per Iyer et al., 1989, Peptides journal), which raises serious questions about how any peripherally administered dose reaches the CNS in meaningful concentrations. Stacking these with GLP-1 agonists adds another layer of concern. There is zero published data on interactions between selank or DSIP and semaglutide or tirzepatide. Recommending that stack to a general audience is irresponsible regardless of how it's framed.

What should you actually know?

If you're interested in selank because you struggle with anxiety, the honest answer is that the existing data is more credible than average for an unscheduled peptide, but still nowhere near sufficient to recommend it over established, well-studied options. The same goes for DSIP and sleep. Before spending money on compounded peptide vials from an unregulated source, you should know that the FDA has sent warning letters to multiple compounding pharmacies for selling unapproved peptide injectables, and that purity and dosing accuracy vary significantly across suppliers. If a creator is not discussing sourcing standards, half-life limitations, and the absence of long-term safety data in humans, they are giving you an incomplete picture. These are not FDA-approved treatments. They are research chemicals with interesting but preliminary profiles. Anyone framing them as obvious upgrades to your existing GLP-1 regimen is moving faster than the evidence allows, and you are the one absorbing the unknown risk.